NCT04392102已完成2 期
A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients With Advanced and Relapsed Ovarian Cancer After 3 or 4 Previous Chemotherapies
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 15
- 试验地点
- 7
- 主要终点
- Objective Response Rate（ORR）
研究概览
简要总结
This is a Phase 2, open-label, single arm study to evaluate the safety and efficacy of niraparib in ovarian cancer patients who have received three or four previous chemotherapy regimens. Niraparib is an orally active PARP inhibitor. Niraparib will be administered once daily continuously during a 28-day cycle. Health-related quality of life will be measured by Eastern Cooperative Oncology Group performance status (ECOG). Safety and tolerability will be assessed by clinical review of adverse events (AEs), physical examinations, electrocardiograms (ECGs), RECIST tumor assessments and safety laboratory values.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients must be female and at least 18 years of age
- •Patients must provide written informed consent
- •Patients must be gBRCA mutation or HRD positive
- •Patients must have histologically diagnosed high-grade (Grade 2 or 3)serous epithelial ovarian, fallopian tube, or primary peritoneal cancer with recurrent disease.
- •Patients Must have completed 3 or 4 previous chemotherapy regimens.
- •Patients must have measurable disease according to RECIST (v.1.1).
- •Patients must have an Eastern Cooperative Oncology Group(ECOG) performance status of 0 or1
- •Patients must have adequate organ function, defined as follows: a. Absolute neutrophil count≥1500/ul b. Platelets ≥150000/ul c. Hemoglobin≥10g/dL d. Serum creatinine≤1.5X upper limit of normal (ULN)or calculated creatinine clearance≥60ml/min using the Cockcroft-Gault equation e. Total bilirubin≤1.5X ULN OR direct bilirubin≤1X ULN f. Aspartate aminotransferase and alanine aminotransferase≤2.5X ULN unless liver metastases are present, in which case they must be ≤5X ULN
- •Patients must be either postmenopausal, free from menses for>12 months, surgically sterilized, or willing to use adequate contraception to prevent pregnancy or must agree to abstain from heterosexual activity throughout the study, starting with enrollment through 90 days after the last dose of study treatment
- •Patients must have formalin-fixed, paraffin-embedded tumor samples available form primary or recurrent cancer.
- •Patients must be able to take oral medications and capable of complying with treatment and follow up visit
排除标准
- •Patients who have received other investigational drugs within 4 weeks or 5X t1/2 before first dose of study treatment.
- •Patients have had palliative radiotherapy encompassing>20% of the bone marrow within 3 weeks of the first dose of study treatment.
- •Patients have any known, persistent(>4 weeks)，≥Grade 3 anemia, neutrophil count decrease or platelet count decrease during the last chemotherapy.
- •Patients have any known, persistent (>4 weeks), ≥ Grade 3 fatigue during the last chemotherapy.
- •Patients have received pelvic radiotherapy as treatment for primary or recurrent disease within 1 year of the first dose of study treatment.
- •Patients have symptomatic uncontrolled brain or leptomeningeal metastases. The patient have new or progressive signs or symptoms related to the CNS disease and not taking a stable dose of steroids or no steroids. A scan to confirm the absence of brain metastases is not required.
- •Patients have known hypersensitivity to the components of niraparib
- •Patient have had major surgery within 3 weeks of fist dose treatment and patient must have recovered form any effects of any major surgery
- •Patients have had diagnosis, detection, or treatment of invasive cancer other than ovarian cancer ≤2 years prior to enrollment(except basal or squamous cell carcinoma of the skin that has been definitively treated)
- •Patients are considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to:
- •uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction
- •uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome or any psychiatric disorder that prohibits obtaining informed consent
- •immune deficiency (not including splenectomy)
- •HIV infection or active hepatitis(i.e. hepatitis B with HBV-DNA>500IU/ml or hepatitis C with positive HCV-RNA).
- •Patients have received a transfusion (platelets or red blood cells) within 4 weeks of the first dose of study treatment.
- •Patients have known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
- •Patients have current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study or interfere with patient's participation for the full duration of the study treatment or that makes it not in the best interest of the patient to participate
研究组 & 干预措施
ZL-2306(Niraparib)
Experimental
The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
干预措施: ZL-2306(Niraparib） (Drug)
结局指标
主要结局
Objective Response Rate（ORR）
时间窗: Up to 3 years
The ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) as assessed by the Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) (version1.1).
次要结局
- Duration of Response (DoR)(Up to 3 years)
- Disease Control Rate (DCR)(Up to 3 years)
- Progression Free Survival (PFS)(Up to 3 years)
- Overall Survival (OS)(Up to 3 years)
- Number of Participants With Any Non-serious Adverse Event (Non-SAE) or Any SAE To evaluate the safety and tolerability of niraparib(Up to 3 years)
研究者
研究点 (7)
Loading locations...
相似试验
已完成
2 期
A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy RegimensOvarian NeoplasmsOvarian CancerNCT02354586Tesaro, Inc.463
终止
2 期
Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic CancerMetastatic Pancreatic CancerNCT05442749Centre Leon Berard2
已完成
2 期
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer ParticipantsNeoplasmsNCT03308942Tesaro, Inc.53
招募中
2 期
Niraparib and Dostarlimab in HRD Solid TumorsHomologous Recombination Deficient Solid TumorsNCT04983745West Cancer Center30
已完成
2 期
Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based ChemotherapyUrothelial CarcinomaNCT03945084University of Turin, Italy58